Plandai Biotechnology Inc. (PLPL) Provides Update to Its Proprietary Technology

Plandai is Gaelic for “plant food” and references the Company’s origins in Ireland over fifteen years ago with a vision to take all-natural nutraceutical ingredients and unlocking their pharmaceutical potential by delivering a therapeutic level of essential plant-based nutrients to human cells.

Callum Cottrell-Duffield, Chief Operating Officer of Plandai, summarized, “Science has shown that plants have tremendous curative properties.  However, current extraction methods fail to produce products that can be properly absorbed and remain in the system long enough for a therapeutic effect.  Plandaí alone possesses the technology to restructure plant nutrients into a highly-purified form that the body can more easily process while also increasing their absorption into the blood plasma and the length of time those nutrients remain present and active in your system.  The end result is that Phytofare® is simply the purest possible plant extract rendered in an extremely powerful and natural state.  Simply put, we are able to finally unlock nature’s potential.”

Phytofare® products are specially formulated to have extremely high bioavailability. In practical terms, this means that Plandai can deliver more of the vital plant nutrients to the blood plasma where it remains at a therapeutic level for over 24 hours. Compared to generic green tea extracts:

1. Phytofare® contains all of the phyto-nutrients in a stable, active extract. For example, with green tea, Phytofare® has all 8 catechins compared to just 2 in generic. The different is greater efficacy and improved synergy.

2. Phytofare® consists of mostly sub-micron sized particles which enhances cellular uptake.

3. Phytofare® is more bioavailable than generic extracts. In fact, it is clinically proven to have 10-16 times greater bioavailability.

4. Phytofare has 4 times greater residency in the blood plasma, 24 hours compared to 6. This means it can be an effective “once a day” dose.

5. Phytofare® offers greater stability over generic. Studies have shown that Phytofare® still retains over 70% of its catechin efficacy after 90-day exposure, whereas generic catechins are completely gone.

6. Phytofare® cost per dose is a fraction of its nearest competitor.

Mr. Cottrell-Duffield concluded, “Plandai has proven that botanical extracts can be produced with pharmaceutical properties and potential.  The phyto-availability of Phytofare® extracts can lead to a new family of all-natural, homeopathic cost-effective wellness products developed from the botanical pharmacopeia—without the high cost associated with other drug-based treatments, and the toxic side effects usually associated with them, including the creation of drug resistance.”

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include animal husbandry, dietary supplements, diabetes and cannabis. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit: https://www.plandaibiotech.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company’s filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.